Skip to main navigation Skip to search Skip to main content

Validation of an 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for β-amyloid plaques

  • Shiaw Pyng Wey
  • , Chi Chang Weng
  • , Kun Ju Lin
  • , Cheng Hsiang Yao
  • , Tzu Chen Yen
  • , Hank F. Kung
  • , Daniel Skovronsky
  • , Mei Ping Kung*
  • *Corresponding author for this work
  • Chang Gung Memorial Hospital
  • University of Pennsylvania
  • Eli Lilly
  • Chang Gung University

Research output: Contribution to journalJournal Article peer-review

15 Scopus citations

Abstract

Aim: Recently, the feasibility of detecting amyloid plaques in the living brain by positron emission tomography (PET) imaging has been successfully demonstrated. As such, imaging β-amyloid (Aβ) plaques in the brain may further advance the differential diagnosis of the disease and allow clinicians to measure the effectiveness of therapeutic drugs aimed at lowering plaques in the brain. We report herein the preclinical validation of a potential 18F-labeled biphenylalkyne, AV-138, as a preliminary step toward developing the imaging agent for patients suspected of having Alzheimer's disease. Methods: In vitro binding was carried out in the homogenates prepared from postmortem AD brains with [125I]IMPY as the radioligand. [18F]AV-138 was successfully prepared using a tosylate precursor and Sumitomo modules for radiosynthesis. Similarly, specific binding of [18F]AV-138 (0.02-0.05 nM) to homogenates, prepared from gray and white matters of pooled AD patients and control subjects, was performed. Specific binding to Aβ plaques was measured by autoradiography in AD brain sections (n=11), and the same brain sections were fluorescently stained with thioflavin-S (TF-S). Images of both radiolabeling and fluorescent staining of plaques obtained by a phosphor imager were used for correlation image analysis. Results: As expected, AV-138 displayed a high binding affinity (Ki=2.4±0.7 nM) in AD gray matter homogenates (due to its high level of Aβ plaque accumulation). Specific binding can be clearly measured in the AD gray matter homogenates, but not in the AD white matters. Control brain homogenates, due to a lack of Aβ plaques, also showed no specific binding. Furthermore, in vitro autoradiography of postmortem AD brain sections showed that the high binding signal of [18F]AV-138 was specifically due to Aβ plaques. Fluorescent staining of plaques with TF-S correlated well with the radiolabeling of [18F]AV-138 in AD brain sections (r>0.90). Conclusion: Taken together, these preliminary results strongly suggest that [18F]AV-138 is potentially useful for imaging Aβ plaques in the living human brain.

Original languageEnglish
Pages (from-to)411-417
Number of pages7
JournalNuclear Medicine and Biology
Volume36
Issue number4
DOIs
StatePublished - 05 2009

Keywords

  • Alzheimer's disease
  • Autoradiograph
  • Brain imaging
  • In vitro binding
  • Radiofluorination

Fingerprint

Dive into the research topics of 'Validation of an 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for β-amyloid plaques'. Together they form a unique fingerprint.

Cite this